2730
Both raloxifene (RLX) and alendronate (ALN) can treat and prevent new vertebral fractures, increase bone mineral density (BMD), and decrease biochemical markers of bone turnover in postmenopausal women with osteoporosis.
 postmenopausal women with osteoporosis: Subject; osteoporosis: Subject.Disorder; increase bone mineral density (BMD): Effect; decrease biochemical markers of bone turnover: Effect; Both raloxifene (RLX) and alendronate (ALN): Treatment; vertebral fractures: Treatment.Disorder; raloxifene: Treatment.Drug; alendronate: Treatment.Drug
Given event type and trigger, please tell me the arguments of all the listed option. Output format is "name1: role1; name2: role2". 
Event type: potential therapeutic event 
  Option: Treatment.Freq, Subject.Population, Combination.Drug, Subject.Gender, Treatment.Duration, Subject, Effect, Treatment, Treatment.Disorder, Treatment.Time_elapsed, Subject.Disorder, Subject.Race, Treatment.Route, Treatment.Dosage, Subject.Age, Treatment.Drug 
Text: {0} 
Answer:
 postmenopausal women with osteoporosis: Subject; osteoporosis: Subject.Disorder; increase bone mineral density (BMD): Effect; decrease biochemical markers of bone turnover: Effect; Both raloxifene (RLX) and alendronate (ALN): Treatment; vertebral fractures: Treatment.Disorder; raloxifene: Treatment.Drug; alendronate: Treatment.Drug